The U.S. Food and Drug Administration (FDA) has cleared the approval of “Air Next” for people with chronic obstructive pulmonary disease (COPD), asthma or cystic fibrosis.
Air Next is a portable, home-use spirometer device developed by NuvoAir, formerly known as Pond Healthcare Innovation, a Sweden-based company.
NuvoAir submitted the device’s application in November 2018 and received its approval on Thursday, according to the FDA.
The Air Next is a respiratory monitoring device specially designed for patients with COPD, asthma or cystic fibrosis.
The device is connected to iOS or Android smartphones via Bluetooth Low Energy (LE) to conduct forced vital lung capacity and forced expiratory volume tests at the same time.
The readings can be collected on your smartphone, which can be shared with a medical professional.
Air Next entered the European markets in 2018.
NuvoAir is quite eager to expand its plans across the globe and seeks a great opportunity to bring its digital respiratory health platform in the United States.
The new portable spirometer device can help manage your respiratory conditions by allowing you to track the progressing of your disease so that you eventually seek proper medical care. Last year, NuvoAir closed $3 million in a funding round to grow its business and enter new markets. Also, it announced a new partnership with Roche Italy, which would make its respiratory health platform available to cystic fibrosis centers in the nation.
